© 2017 Pharmstandard Ventures
Protagonist Therapeutics
(NASDAQ:PTGX)
Menlo Park, CA, USA & Brisbane, Queensland, Australia
Year of Investment: 2013
(NASDAQ:PTGX)
Menlo Park, CA, USA & Brisbane, Queensland, Australia
Year of Investment: 2013
IPO in August, 2016
Strategic Deal with Janssen in May, 2017
Strategic Deal with Janssen in May, 2017
Protagonist Therapeutics
(NASDAQ:PTGX)
Menlo Park, CA, USA & Brisbane, Queensland, Australia
Year of Investment: 2013
(NASDAQ:PTGX)
Menlo Park, CA, USA & Brisbane, Queensland, Australia
Year of Investment: 2013
IPO in August, 2016
Strategic Deal with Janssen in May, 2017
Strategic Deal with Janssen in May, 2017
A Protagonist is a clinical-stage biopharmaceutical company developingfirst-in-class oral peptide drugsthat specifically target biological pathways involved in inflammatory bowel disease (IBD), also targeted by currently marketed injectable antibody drugs. Compared to injectable antibody drugs, oral peptides offer targeted delivery to the gastrointestinal (GI) tissue compartment, potential for improved safety due to minimal exposure in the blood, improved convenience and compliance due to oral delivery, and the opportunity for earlier introduction of targeted therapy.
For more information, please visit:
www.protagonist-inc.com
For more information, please visit:
www.protagonist-inc.com
Pharmstandard Ventures is looking for innovative drug discovery/development projects targeting the unmet medical needs or providing dramatic advantages over the competition globally